Skip to main content

Security report for enspryng.com

Genentech · Healthcare · United States

Low risk. 2 critical or high findings in Security headers and SSL/TLS.

Security score

81/100

Risk levelLow

0–100, higher is better. How it is calculated

The website www.enspryng.com represents Genentech's pharmaceutical product ENSPRYNG®, a treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD). The site provides detailed patient-focused information, healthcare professional resources, and access to medication guides and prescribing information. The business is positioned as an established biotechnology company with a specialty drug offering, targeting patients and clinicians. Technically, the site is built on Adobe Experience Manager with modern web technologies, including consent management and analytics tools, reflecting a mature digital infrastructure. Security posture is good with HTTPS, reCAPTCHA, and cookie consent mechanisms, though explicit security headers and policies are not fully documented. The absence of WHOIS registration data is a concern for domain legitimacy, but the site content and branding align with a reputable pharmaceutical entity. Overall, the site is professional, secure, and compliant with privacy norms, though improvements in transparency of security and privacy policies are recommended.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching enspryng.com

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
75
Security headers
55
Email security
85
DNS health
80
Network security
100
GDPR outside view
88
Average
81

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Genentech leverages this site to support its ENSPRYNG product by providing comprehensive treatment information and patient support. The business model focuses on pharmaceutical product marketing and patient engagement. The site links to healthcare professional portals and regulatory documents, indicating a strong compliance and educational focus. Market positioning is solid within the biotechnology sector, with a clear target audience of patients and clinicians. The partnership ecosystem includes Genentech's main corporate site and healthcare professional resources. Growth indicators include detailed clinical trial results and patient stories, enhancing trust and engagement.

Security posture

The website demonstrates a moderate to strong security posture with enforced HTTPS, use of Google reCAPTCHA to mitigate automated abuse, and a cookie consent banner indicating GDPR awareness. However, explicit security policies, incident response contacts, and vulnerability disclosure mechanisms are absent, representing gaps in transparency and readiness. No critical vulnerabilities or exposed sensitive data were detected in the analysis. The site uses modern monitoring tools like New Relic, which supports proactive performance and security monitoring. Recommendations include publishing security policies, implementing a vulnerability disclosure program, and ensuring all security headers are explicitly set.

Recommendations

  1. Publish a clear privacy policy page accessible from the main navigation or footer.
  2. Implement and publish a formal security policy and incident response plan.
  3. Add a vulnerability disclosure policy or security.txt file to encourage responsible reporting.
  4. Verify and update WHOIS registration to ensure domain legitimacy and transparency.
  5. Enhance security headers such as X-Frame-Options and X-Content-Type-Options for improved protection.

Contact details published on the site

Addresses
Legal name
Genentech
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Genentech
Description
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. ENSPRYNG® (satralizumab) is a self-administered, monthly treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD).
Key services
ENSPRYNG treatment information, patient support resources, healthcare professional resources
Content quality
good
Branding
consistent

Technology

Stack
Adobe Experience Manager (AEM), Google reCAPTCHA, OneTrust Cookie Consent, Font Awesome, New Relic monitoring, JavaScript, HTML5, CSS3
Frameworks
Adobe Experience Manager
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • Use of reCAPTCHA for bot protection
  • Cookie consent banner implemented

Analytics and tracking

Services
Adobe Analytics, New Relic
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
New Relic
Marketing tools
Adobe Analytics, OneTrust Consent Management
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with rich content about ENSPRYNG treatment.
  2. No WHOIS data available, which is unusual for a commercial domain.
  3. Site uses modern web technologies and consent management.
  4. No explicit contact emails found, but phone and address info present in structured data.
  5. No security or incident response policies published on site.
  6. No vulnerability disclosure or security.txt found.
  7. Content is safe and targeted at patients and healthcare professionals.
  8. External links mostly to trusted domains related to Genentech and regulatory documents.
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS platform, indicating a high level of technical maturity. It uses modern front-end technologies including Font Awesome for icons, Google Fonts for typography, and integrates third-party services like Google reCAPTCHA and OneTrust for consent management. Performance is moderate with asynchronous loading of scripts and use of CDN-hosted resources. Mobile optimization and accessibility are well addressed, with responsive design and skip-to-content links. SEO is supported by comprehensive meta tags and structured data in JSON-LD format. Technical risks are minimal but include reliance on external scripts and the need for regular updates to third-party libraries.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with enspryng.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review enspryng.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.